Oncology Biosimilars Market Report 2026

The oncology biosimilars market size has grown rapidly in recent years. It will grow from $11.35 billion in 2025 to $12.83 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to high cost of reference biologics, limited availability of oncology biosimilars, increasing cancer prevalence globally, growing hospital and pharmacy infrastructure, early regulatory approvals for monoclonal antibody biosimilars.

The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $21.28 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to launch of new biosimilar drugs including pembrolizumab and pegfilgrastim, expansion of online pharmacy distribution channels, rising adoption of immunomodulators and hematopoietic agents, increasing government initiatives to improve cancer care access, growing focus on personalized oncology treatment. Major trends in the forecast period include rising adoption of rituximab, trastuzumab, and bevacizumab biosimilars, increasing use of immunomodulators and hematopoietic agents in cancer therapy, growth in g-csf biosimilars for neutropenia management, expansion of hospital and retail pharmacy channels for oncology biosimilars, focus on cost-effective and accessible cancer treatment options.

The expiration of patents for biologics used in cancer treatment is encouraging the development of new oncology biosimilars. Biologics are protected by patents for a limited duration, and once these patents expire, it becomes possible to develop biosimilar alternatives. Biologics are targeted therapies derived from living organisms that stimulate the immune system to fight cancer cells. Biosimilars closely resemble biologics but are not exact replicas, offering comparable effectiveness at a lower cost. For example, in February 2024, according to DrugTimes, a China-based company focused on the pharmaceutical and biotechnology industry, more than 25 products are expected to lose patent protection by 2037, potentially leading to a combined revenue decline of over $236.4 billion based on 2024 sales figures. The rising number of patent expirations is anticipated to increase demand for the development of new oncology biosimilars, thereby driving growth in the oncology biosimilars market.

Leading companies in the oncology biosimilars market are concentrating on the development of advanced cancer therapies, including targeted biologics and monoclonal antibodies, to improve treatment effectiveness, patient outcomes, and overall accessibility in oncology care. Monoclonal antibodies (mAbs) are laboratory-developed proteins designed to identify and bind to specific antigens on cancer cells, allowing precise targeting and immune-driven destruction. For instance, in March 2023, Pfizer, a US-based pharmaceutical company, merged with Seagen and invested $43 billion to strengthen its oncology portfolio. This strategic initiative enhances Pfizer’s position in cancer therapeutics and accelerates the development of advanced cancer treatments, addressing one of the leading causes of death globally. The investment also highlights the growing trend of substantial capital deployment toward innovative oncology biosimilars to meet unmet medical needs and expand global access to cancer care.

In October 2024, Teva Pharmaceuticals Inc., an Israel-based pharmaceutical company, entered into a partnership with mAbxience to advance next-generation oncology biosimilar solutions. This collaboration focuses on expanding access to and advancing the development of high-quality oncology biosimilars, with the goal of improving patient outcomes in cancer treatment while supporting innovation and growth within the oncology biologics market. mAbxience S.A. is a Spain-based biopharmaceutical company specializing in the development and commercialization of monoclonal antibody biosimilars.

Major companies operating in the oncology biosimilars market are Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech.

North America was the largest region in the global oncology biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oncology biosimilars market by raising costs of imported biologics, monoclonal antibodies, and active pharmaceutical ingredients. Hospital and retail pharmacy channels in regions such as North America and Europe, which rely on imports, are most affected. This has increased treatment costs and slowed market growth in short term. On the positive side, tariffs have encouraged local production, domestic R&D investments, and innovation in cost-effective biosimilar therapies, improving long-term access and affordability.

The oncology biosimilars market research report is one of a series of new reports that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with a oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oncology biosimilars are biologically similar drugs that closely resemble existing biologic cancer therapies in terms of safety, purity, and effectiveness. They are used to manage treatment-related effects such as reduced white blood cell counts, which increase the risk of infection during cancer therapy.

The primary drug types of oncology biosimilars include monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that mainly target immune pathways involved in the treatment of multiple myeloma and certain other cancers. These biosimilars are used to treat cancers such as breast cancer, colorectal cancer, blood cancer, neutropenia-related conditions, and non-small cell lung cancer, and they are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.